Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide [101] . Surgical resection is the mainstay of curative treatment. However, no more than 30% of HCC patients are considered suitable for surgical treatment because of tumor size, multifocal tumors, vascular invasion, presence of extrahepatic metastases and/or extensive liver impairment. The majority of patients with HCC have underlying cirrhosis, most commonly due to hepatisis B or C viral infection, which may restrict the feasibility of surgical resection even with small tumors. Liver transplantation is an alternative curative treatment, but its application is limited by a severe shortage of liver graft donors. Thermal ablation modalities such as radiofrequency ablation (RFA), microwave ablation and high-intensity focused ultrasound have emerged as important treatment options for such patients in recent years [1] .
During RFA, radiofrequency waves emitted from an electrode inserted into the tumor induce vibration of ions in the cancer cells, which causes frictional heat and thermal coagulative necrosis of the cells. RFA monotherapy is a curative treatment for HCC tumors ≤3 cm. It is a safe treatment with a morbidity rate of less than 10% and a mortality rate of approximately 0.5% [2] . It is the most commonly used treatment for patients with small HCC associated with significant cirrhosis not suitable for resection. Whether it can replace resection as the treatment of small HCC in patients with good liver function remains controversial. A randomized trial has shown that RFA can achieve longterm survival rates for small HCC that are similar to resection [3] , but a more recent randomized trial demonstrated that survival and recurrence rates were better with resection than RFA [4] . The efficacy of RFA is significantly influenced by tumor size. For patients with lesions too big to be treated within a single ablation zone (those with lesions >3 cm, approximately half of the HCC population), RFA is much more likely to leave viable tumor cells in the margins or clefts of overlapping ablation zones. Local recurrence rates after RFA for tumors ≤3 cm are reported to be ≤20% [5] [6] [7] [8] [9] ; however, for tumors >3 cm, local recurrence rates of ≥40% have been observed [10, 11] .
Lyso-thermosensitive liposomal doxorubicin (LTLD; ThermoDox ® [Celsion Corp., MD, USA]) is designed for use with RFA and consists of the heat-enhanced cytotoxic anthracycline anti biotic doxorubicin within a heat-activated liposome. This article reviews the rationale and preliminary clinical data of its combined use with RFA for liver cancer and discusses its potential role in the future oncological treatment of HCC.
Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. No more than 30 % of HCC patients are considered suitable for curative treatment because of tumor size and severity of liver impairment, among other factors. Radiofrequency ablation (RFA) monotherapy can cure small (<3 cm) HCC tumors. An adjuvant that interacts synergistically with RFA might enable curative therapy for many HCC patients with lesions >3 cm. Lysothermosensitive liposomal doxorubicin (LTLD) consists of the heat-enhanced cytotoxic doxorubicin within a heat-activated liposome. LTLD is infused intravenously prior to RFA. When heated to >39.5°C, LTLD releases doxorubicin in high concentrations into the tumor and the tumor margins. The RFA plus LTLD combination has shown a statistically significant dose-response effect for time to treatment failure in a Phase I trial in which most subjects (62.5%) had tumors >3 cm. RFA plus LTLD is currently being evaluated in a 600-patient randomized, double-blind, dummy-controlled trial. 
Drug Evaluation Poon & Borys Rationale
A review of 13 published trials of single-agent doxorubicin among 644 HCC patients found an objective response rate of 19% and median overall survival of 4 months [12] . In subsequent randomized trials comparing overall survival, single-agent doxorubicin has been found to be superior to no anticancer treatment [13] , equivalent to combination chemotherapy with cisplatin, IFN-a-2b, doxorubicin and fluorouracil [14] and superior to single-agent nolatrexed [15] . However, systemic doxorubicin has not become a standard treatment for HCC due to its relatively high incidence of severe toxicity, including congestive heart failure and neutropenia [13] [14] [15] .
Lyso-thermosensitive liposomal doxorubicin is administered intravenously but, because it is a liposome, rapidly concentrates in the liver and spleen [16] . Since LTLD is larger than free doxorubicin, it is over 1000-times less permeable across normal blood vessels than free doxorubicin, offering less potential for systemic toxicity. However, tumors have much higher micro vascular permeability than normal blood vessels, so LTLD is able to accumulate in tumors [16, 17] . In addition, hyperthermia has been shown to preferentially increase liposomal permeability within the microvasculature in tumor versus normal tissue. Hyperthermia has a biological effect of increasing the pore size in tumor blood vessels, and therefore enhancing the extravasation of liposomes into the tumor interstitium. Studies demonstrated that tumors that were impermeable to liposomes at 34°C had significant extravasation and thus increased permeability at 42°C. The optimal liposome size for heat-induced extravasation was found to be 100 nm (the mean diameter of LTLD). The same effect was not observed in normal tissue [18, 19] . Therefore, it can be hypothesized that hyperthermia induces preferential extravasation of liposomes in tumor tissue compared with healthy tissue. The benefits of hyperthermia with thermosensitive liposomes for the delivery of chemotherapeutic agents are twofold: enhanced localization of the liposomes into the tumor interstitium, coupled with a triggered and rapid release of the drug in the tumor and the tumor vasculature.
Within 30 s of exposure to temperatures of ≥39.5°C, LTLD releases its doxorubicin contents, creating a large concentration gradient of doxorubicin around the zone of RFA-induced tumor cell necrosis. Preclinical studies found that at temperatures of ≥39.5°C, LTLD produces doxorubicin tumor concentrations up to 15-fold greater than free (nonliposomal) doxorubicin administered at the same doses [Celsion Corp., Unpublished Data]. The doxorubicin then kills any tumor cells adjacent to the ablation zone, providing more successful treatment of HCC lesions >3 cm than thermal ablation alone. In vitro studies have repeatedly shown enhancement of cell killing when doxorubicin is combined with hyperthermia compared with doxorubicin without hyperthermia [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . This enhancement has been attributed to the ability of hyperthermia to increase intracellular retention of chemotherapeutic agents by upregulating their influx [20, 26] .
Overview of strategies to improve RFA treatment for HCC Box 1 summarizes initiatives to increase the HCC cure rate by combining another therapy with RFA. This article will not deal with proposals to increase the efficacy of RFA alone (e.g., better guidance with contrast-enhanced ultrasound, fusion imaging or robotics; redesigning RFA electrodes; or improving treatment algorithms to magnify the ablation zone) [32] [33] [34] . One approach aims to improve the cure rate in multifocal disease by performing surgical resection on resectable tumors and RFA on unresectable lesions [35] . A strategy for tumors >3 cm is to perform transarterial chemoembolization (TACE) to downsize the tumors so they are more curable with RFA [36] . Thus far, randomized trial findings for this combination are modest. Morimoto et al. randomized 37 patients with solitary medium (3.1-5.0 cm) HCC lesions to RFA plus TACE or RFA alone [37] . After 3 years, the RFA plus TACE group had a statistically significant advantage in local tumor control, but not in overall survival. Wang et al. randomized 83 patients, of whom 59% had lesions >3 cm, to RFA plus TACE or RFA alone [38] . The RFA plus TACE group had a statistically significant advantage in 'quality of life', but not in recurrence rate. Yang et al. random ized 36 patients with large (>5 cm) HCC lesions to RFA plus TACE or RFA alone [39] . The two groups did not differ significantly in either relapse rate or overall survival. A frequent suggestion for tumors >3 cm in the literature is to perform RFA and then to administer a systemic treatment to eradicate any residual tumor. Therapy with interferon [40, 41] , sorafenib (or other molecularly targeted agents once available) [42] [43] [44] and vitamin A or vitamin K analogs [45] have been recommended. In the simultaneous RFA plus LTLD approach, LTLD is administered systemically but rapidly concentrates in the liver, where it acts synergistically with RFA. future science group
Lyso-thermosensitive liposomal doxorubicin Drug Evaluation Introduction to LTLD Chemistry
Lyso-thermosensitive liposomal doxorubicin is the first heat-activated formulation of liposomal doxorubicin. The active drug in LTLD is doxorubicin hydrochloride. Doxorubicin consists of a naphthacenequinone nucleus linked through a glycosidic bond at ring atom 7 to an amino sugar, daunosamine. The chemical formula is C 27 H 29 NO 11 •HCl and the molecular weight is 579.99 Da. LTLD combines doxorubicin with lyso-thermosensitive liposomes that are made from three synthetic phospholipids: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxypolyethylene-glycol-2000. LTLD is manufactured as stable doxorubicinloaded liposomes, which are stored as a frozen solution [Celsion Corp., Unpublished Data].
Pharmacodynamics
For single LTLD doses, the plasma half-life (mean ± standard deviation of 24 patients) is 18.52 ± 8.36 h. Initial evaluation of two cycles of LTLD, 21 days apart, suggests that there does not appear to be any appreciable accumulation of doxorubicin between LTLD infusions [Celsion Corp., Unpublished Data].
Pharmacokinetics & metabolism
The major portion of exposure to LTLD (~95% of the liposomal doxorubicin plasma area under the curve [AUC] 0-∞ ) occurs during the first 6 h following the infusion, establishing this time period as optimal for application of RFA. Most of the free doxorubicin exposure also occurs during the first 6 h (87.9% of the free doxorubicin AUC 0-∞ ). Free doxorubicin represents 43.6% of the total doxorubicin AUC 0-∞ . For both liposomal and free doxorubicin, maximum plasma concentration occurs just before the end of the 30-min infusion [Celsion Corp., Unpublished Data].
Clinical efficacy
Phase I studies A 24-subject trial (nine with HCC and 15 with metastatic liver tumors from nine other primary sites) has been completed. A total of 15 (62.5%) of the 24 subjects had tumors >3.0 cm [Celsion Corp., Unpublished Data]. Treatment failure was operationally defined as objective disease progression and/or initiation of an alternative anti cancer therapy. There was a statistically significant (p = 0.038) LTLD dose-response effect: median time to treatment failure for patients receiving at least the maximum tolerated dose of 50 mg/m 2 was 374 days, while that for patients receiving less than 50 mg/m 2 was 80 days. Time to treatment failure was significantly associated with LTLD dose but not with tumor size (≤3 cm or >3 cm), tumor type (HCC or metastatic liver cancer) or RFA type (open surgical or percutaneous) (TaBle 1) . There were three subjects at the 60 mg/m 2 dose level. None of these three subjects experienced treatment failure; they were censored at 122, 283 and 337 days. Furthermore, there were four subjects with tumors >5 cm in the trial. Of these, the two subjects treated at <50 mg/m 2 experienced treatment failure at 25 and 93 days, respectively, while the two subjects treated at ≥50 mg/m 2 experienced treatment failure at 261 and 374 days, respectively [Celsion Corp., Unpublished Data]. These very limited data in large liver lesions are again suggestive of a LTLD dose-response relationship.
Phase II studies
Owing to promising Phase I results, the developers of LTLD worked with the US FDA and proceeded directly into Phase III testing. Box 1. Radiofrequency ablation-based combination therapies to increase the hepatocellular carcinoma cure rate.
Surgery for resectable tumors and RFA for unresectable tumors (efficacy additive)
n RFA plus partial hepatectomy [35] Precede RFA with local treatment to downsize tumor (efficacy additive) n TACE plus RFA [36] [37] [38] [39] Follow RFA with systemic therapy to eradicate any residual tumor (efficacy additive) n RFA plus interferon [40, 41] n RFA plus sorafenib (or newer molecularly targeted agents) [42] [43] [44] n RFA plus vitamin analogs [45] Simultaneous RFA and heat-enhanced, organ-specific chemotherapy (efficacy synergistic) n RFA plus lyso-thermosensitive liposomal doxorubicin [47] RFA: Radiofrequency ablation; TACE: Transarterial chemoembolization.
future science group
Drug Evaluation Poon & Borys
Phase III studies A randomized, double-blind, dummy-controlled, multicenter Phase III trial ('HEAT study') is underway, comparing RFA/LTLD with RFA alone among 600 patients with unresectable HCC. Child-Pugh class A or B patients are eligible, except that both ascites and encephalo pathy are exclusionary. Eligible patients can have no more than four HCC lesions with at least one ≥3.0 cm and none >7.0 cm in maximum diameter. However, if a patient has a large lesion (5.0-7.0 cm), any other lesions must be less than 5.0 cm. In both arms, RFA may be performed percutaneously, laparoscopically or surgically, per the investiga-or surgically, per the investiga-or surgically, per the investigators' clinical judgment. Patients in the combination arm will receive a single 30-min intravenous infusion of LTLD at 50 mg/m 2 , starting 15 min before RFA; the RFA-only arm patients will receive a dummy infusion. Progression-free survival is the primary end point. Secondary end points include overall survival, time to local recurrence and time to a clinically significant deterioration in patient self-reported symptoms. The National Cancer Institute of the USA has recommended the HEAT study as a priority clinical trial for HCC [46] .
Lyso-thermosensitive liposomal doxorubicin is not approved for use yet. However, this pivotal trial has randomized 556 of the 600 HCC subjects at the time of writing this article. It is expected that the Phase III trial will produce data robust enough to test the hypothesis that LTLD in combination with RFA could increase the cure of medium/large HCC.
Safety & tolerability
The maximum tolerated dose of LTLD was determined to be 50 mg/m 2 in the Phase I trial, based on two dose-limiting toxicities (grade 3 alanine aminotransferase increase and grade 4 neutropenia) at a dose of 60 mg/m 2 [Celsion Corp., Unpublished Data]. LTLD was not associated with either hand-foot syndrome or with congestive heart failure. The most common LTLD grade 3+ adverse events (affecting ≥5% of patients) were aspartate aminotransferase abnormalities (40.0%), alanine aminotransferase abnormalities (32.7%), neutropenia (29.1%), leukopenia (12.7%) and lymphopenia (9.1%). Very few of the abnormalities in liver function were associated with LTLD. The most common LTLD drug-related adverse events (affecting ≥5% of patients) were alopecia (36.4%), neutropenia (32.7%), leuko penia (20.0%), decreased hemoglobin (18.2%), fatigue (14.5%), nausea (10.9%), thrombocytopenia (9.1%), decreased ejection fraction (9.1%), anorexia (7.3%), taste alteration (5.5%) and fever (5.5%) (TaBle 2). All of the 
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Metabolic The clinical benefit of the RFA plus LTLD combination is hypothesized to be an increased chance of cure of medium/large HCC lesions. The clinical benefit of the standard-of-care treatments for medium/large HCC (TACE or sorafenib) is limited to only some increase in survival. Currently, the role of RFA alone as a curative treatment for HCC >3 cm remains uncertain because of high recurrence rates. By adding LTLD, there is a potential to reduce recurrence and enhance the curative efficacy of RFA for HCC >3 cm, but this has to be corroborated by the data from the ongoing Phase III trial. All of the proposed RFA-based combination therapies to increase the HCC cure rate are hypothesized to have a mainly additive efficacy. The RFA plus LTLD combination is hypothesized to have a synergistic efficacy, since both the tumor specificity and the antitumor activity of LTLD are enhanced by the heat of RFA.
Conclusion & future perspective
As LTLD is a liposome, it rapidly concentrates in the liver, where it permeates HCC lesions and their vasculature. The heat of RFA furthers this process and very quickly releases doxorubicin in the heated area. At the same time, hyperthermia increases the cytotoxicity of doxorubicin, producing a synergistic interaction.
If its curative and synergistic potential is borne out in the Phase III HEAT study, a rational future strategy for HCC lesions >3 cm is to future science group Lyso-thermosensitive liposomal doxorubicin Drug Evaluation employ RFA plus LTLD as a front-line therapy. TACE, sorafenib or another molecularly targeted agent, or one of the other investigational RFA-based combination therapies, can be used as second-line or third-line treatments, if needed. Plans to study combinations of LTLD with other thermal ablative modalities such as highintensity focused ultrasound are being contemplated. The RFA plus LTLD combination also has great potential as a front-line therapy for colorectal liver metastases, but this requires a separate clinical trial.
Executive summary
Mechanism of action
n Lyso-thermosensitive liposomal doxorubicin (LTLD; ThermoDox ® [Celsion Corp., MD, USA]) is designed for use with radiofrequency ablation (RFA) and consists of the heat-enhanced cytotoxic anthracycline antibiotic doxorubicin within a heat-activated liposome. n LTLD is administered intravenously but, because it is a liposome, rapidly concentrates in the liver and spleen. Since tumors have much higher microvascular permeability than normal tissues, LTLD accumulates in liver tumors.
n When LTLD is heated by RFA, a high concentration of doxorubicin is released into the tumor and tumor margins. n Doxorubicin's cytotoxic mechanism of action and its ability to bind to DNA and inhibit nucleic acid synthesis is enhanced by hyperthermia.
Pharmacokinetic properties
n Approximately 95% of the liposomal doxorubicin plasma area under the curve occurs during the first 6 h following infusion, establishing this time period as optimal for application of RFA. The plasma half-life (mean ± standard deviation) is 18.52 ± 8.36 h.
Clinical efficacy
n A statistically significant LTLD dose-response effect for time to treatment failure was found in Phase I.
Safety & tolerability
n Dosage and administration: -Adult: 50 mg/m 2 LTLD infused intravenously over 30 min, with RFA initiated within 15 min of starting the infusion. All RFA procedures should be completed within 3 h. -Pediatric: The safety and efficacy of LTLD has not been studied in children.
n Precautions:
-Administer steroids and multiple histamine receptor blockade beginning 24 h before LTLD to prevent acute infusion reaction. 
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